Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registry
- PMID: 21134545
- DOI: 10.1016/j.surg.2010.10.016
Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registry
Abstract
Background: The incidence of thyroid cancer has more than doubled in recent decades. Debate continues on whether the increasing incidence is a result of an increased detection of small neoplasms or other factors.
Methods: Using the Surveillance, Epidemiology and End Results database, we examined the overall incidence of thyroid cancer with variations based on tumor pathology, size, and stage, as well as the current surgical and adjuvant therapy of thyroid carcinoma.
Results: Thyroid cancer incidence increased 2.6-fold from 1973 to 2006. This change can be attributed primarily to an increase in papillary thyroid carcinoma, which increased 3.2-fold (P < .0001). The increase in papillary thyroid carcinoma also was examined based on tumor size. Tumors ≤ 1 cm increased the most at a total of 441% between 1983 and 2006 or by 19.2% per year, the incidence of papillary thyroid carcinoma also increased at 12.3%/year in 1.1-2-cm tumors, 10.3%/year in 2.1-5-cm tumors, and 12.0%/year for > 5-cm tumors (all P < .0001 by Cochran-Armitage trend test). We also demonstrated a positive correlation between papillary thyroid carcinoma tumor size and stage of disease (Spearman, r = 0.285, P < .0001). Operative treatment for thyroid cancer also has shifted with total thyroidectomy replacing partial thyroidectomy as the most common surgical procedure.
Conclusion: Contrary to other studies, our data indicate that the increasing incidence of thyroid cancer cannot be accounted for fully by an increased detection of small neoplasms. Other possible explanations for the increase in clinically significant (> 1 cm) well-differentiated thyroid carcinomas should be explored.
Copyright © 2010 Mosby, Inc. All rights reserved.
Similar articles
-
Pediatric papillary thyroid carcinoma: outcomes and survival predictors in 2504 surgical patients.Pediatr Surg Int. 2016 Mar;32(3):201-8. doi: 10.1007/s00383-015-3855-0. Epub 2015 Dec 30. Pediatr Surg Int. 2016. PMID: 26717936
-
Do US thyroid cancer incidence rates increase with socioeconomic status among people with health insurance? An observational study using SEER population-based data.BMJ Open. 2015 Dec 7;5(12):e009843. doi: 10.1136/bmjopen-2015-009843. BMJ Open. 2015. PMID: 26644126 Free PMC article.
-
Thyroid cancer, clinical and hystopathological study on patients under 25 years in Tabriz, Iran (2000-2012).Pak J Biol Sci. 2013 Dec 15;16(24):2003-8. doi: 10.3923/pjbs.2013.2003.2008. Pak J Biol Sci. 2013. PMID: 24517019
-
Low risk papillary thyroid cancer.BMJ. 2014 Jun 16;348:g3045. doi: 10.1136/bmj.g3045. BMJ. 2014. PMID: 24935445 Review.
-
[Thyroid carcinomas - current therapeutic procedures].Vnitr Lek. 2016 Fall;62(9 Suppl 3):115-120. Vnitr Lek. 2016. PMID: 27734703 Review. Czech.
Cited by
-
The impact of family history on non-medullary thyroid cancer.Eur J Surg Oncol. 2016 Oct;42(10):1455-63. doi: 10.1016/j.ejso.2016.08.006. Epub 2016 Aug 11. Eur J Surg Oncol. 2016. PMID: 27561845 Free PMC article. Review.
-
Papillary Thyroid Carcinoma Variants are Characterized by Co-dysregulation of Immune and Cancer Associated Genes.Cancers (Basel). 2019 Aug 15;11(8):1179. doi: 10.3390/cancers11081179. Cancers (Basel). 2019. PMID: 31443155 Free PMC article.
-
Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment.PLoS One. 2013 Oct 14;8(10):e77684. doi: 10.1371/journal.pone.0077684. eCollection 2013. PLoS One. 2013. PMID: 24155971 Free PMC article.
-
Comparison of Mean Platelet Volume, Platelet Count, Neutrophil/ Lymphocyte Ratio and Platelet/Lymphocyte Ratio in the Euthyroid, Overt Hypothyroid and Subclinical Hyperthyroid Phases of Papillary Thyroid Carcinoma.Endocr Metab Immune Disord Drug Targets. 2019;19(6):859-865. doi: 10.2174/1871530319666190206125545. Endocr Metab Immune Disord Drug Targets. 2019. PMID: 30727930 Free PMC article.
-
Calcitriol enhances Doxorubicin-induced apoptosis in papillary thyroid carcinoma cells via regulating VDR/PTPN2/p-STAT3 pathway.J Cell Mol Med. 2020 May;24(10):5629-5639. doi: 10.1111/jcmm.15224. Epub 2020 Apr 13. J Cell Mol Med. 2020. PMID: 32285621 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical